MYGN Q3 2020 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q3 2020 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$145M-22.1% YoY

Gross Profit

$101M69.6% margin

Operating Income

-$40M-27.3% margin

Net Income

-$15M-10.5% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+55.8%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$61M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$535M

Stockholders' Equity

$909M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$186M	-22.1%
Gross Profit	$101M	$137M	-26.1%
Operating Income	-$40M	-$21M	-89.5%
Net Income	-$15M	-$21M	+26.2%

Revenue Segments

Diagnostics

$131M90%

Other Segments

$15M10%

Geographic Segments

UNITED STATES

$10M98%

Non-US

$200,0002%